AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers
HIV Infections
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV Vaccines, HIV Seronegativity
Eligibility Criteria
Inclusion Criteria: Healthy volunteers selected by ANRS (French National Agency for Research on AIDS and Viral Hepatitis) For woman of child-bearing age: use of effective contraception Ability to sign informed consent Beneficiary subjects of social security regimen-- Hepatitis B, hepatitis C, HIV, HTLV1 infection and syphilis negative Hemoglobin over 12.5 g/dl for women and over 13.5 g/dl for men Exclusion Criteria: Previous participation in an HIV clinical trial Volunteers with risk to contract HIV infection during the trial Previous vaccination in the last month, and volunteers requiring vaccination during the trial Gift of blood in the last 2 months Eczema, urticaria Medical history of food allergy, Lyell or Stevens Johnson syndrome and aggravated asthma Previous (last 6 months) or ongoing administration of immunological treatment, chemotherapy, radiotherapy or corticosteroid Medical history of autoimmune disease Clinical or biological aftermath of previous disease Medical history of uveitis Transfusion in the last 6 months
Sites / Locations
- CIC de Vaccinologie Cochin Pasteur